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Purpose
Uveal melanoma has a very poor prognosis despite successful local primary tumor treat-
ment. In this study, we investigated prognostic factors that more accurately reflected the
likelihood of recurrence and survival and delineated a prognostic model that could effectively
identify different risk groups based on initial clinical parameters. 
Materials and Methods
Prognostic factors associated with distant recurrence, recurrence-free survival (RFS), pro-
gression-free survival, and overall survival from distant recurrence to death (OS2) were 
analyzed in 226 patients with stage I-III uveal melanoma who underwent primary local ther-
apy. 
Results
Forty-nine patients (21.7%) had distant recurrences, which occurred most frequently in the
liver (87.7%). In a multivariate analysis, local radiotherapy improved RFS among patients
with multiple recurrence risk factors relative to excision (not reached vs. 19.0 months,
p=0.004). Patients with BRCA1-associated protein-1 (BAP1)negative primary tumors
showed a longer RFS duration after primary treatments, while those with BAP1-negative
metastatic tissues had a  shorter OS2 compared to those with BAP1-positive tumors, both
not statistically insignificance (RFS: not reached vs. 82.0 months, p=0.258; OS2: 15.7 vs.
24.4 months, p=0.216). Male sex (hazard ratio [HR], 3.79; p=0.012), a short RFS (HR, 4.89;
p=0.014), and a largest metastatic tumor linear diameter  45 mm (HR, 5.48; p=0.017)
were found to correlate with worse post-recurrence survival. 
Conclusion
Risk factors could be used to classify uveal melanoma cases and subsequently direct indi-
vidual treatment strategies. Furthermore, metastasectomy appears to contribute to 
improved survival outcomes. 
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Introduction
Uveal melanoma, the most common primary intraocular
cancer, has a very poor prognosis, with reported median
overall survival durations of 4-15 months [1-3]. Uveal
melanoma is usually asymptomatic and is often diagnosed
incidentally during routine ophthalmic examinations. 
Accordingly, appropriate treatment is often delayed. 
Although primary uveal melanomas are often successfully
eradicated, nearly 50% of patients develop systemic metasta-
tic disease [2], which almost always involves the liver (89%)
[3]. Metastases of uveal melanoma are rarely detectable at
the time of the first local ocular treatment, and recent studies
have shown that patients undergo routine liver ultrasonog-
raphy screening to detect metastatic sites [4]. However, no
standard screening protocol for uveal metastases currently
exists, and ultrasonography alone often fails to detect hepatic
sites.
Chemotherapeutic agents such as dacarbazine or gemc-
itabine/treosulfan are often administered to patients in
whom recurrent uveal melanoma has been detected, 
although limited evidence supports the use of these regi-
mens. Specifically, these patients rarely exhibit clinical 
responses, and therefore the efficacy of systemic chemother-
apy is questionable [1]. Currently, the immunotherapeutic
agents nivolumab and pembrolizumab, which are fully
human monoclonal antibodies specific for the programmed
cell death protein 1 (PD-1) receptor, have been approved in
the United States for the treatment of advanced melanoma.
However, PD-1 inhibitors have not been demonstrated to 
improve the survival of patients with uveal melanoma, and
previous studies reported a median progression-free survival
(PFS) and overall response rate of only 3 months and 3.6%,
respectively [5,6].  
Several groups have studied the prognostic factors of uveal
melanoma. For example, Harbour et al.  [7] reported an 
inactivating somatic mutation of BAP1, the gene encoding
BRCA-associated protein 1 (BAP1), in predominantly meta-
static uveal melanomas. This mutation was later found to
correlate strongly with the risk of metastasis [8]. Another
study demonstrated associations of ciliary body involve-
ment, the largest tumor diameter, and extraocular extension
with a significantly poor prognosis in patients with uveal
melanoma [9].
In the present retrospective study, we identified prognostic
predictors of distant recurrence and survival after recurrence
in 226 patients with uveal melanoma who received primary
local therapy at our hospital between 1990 and 2015. We
aimed to study the time interval between the diagnoses of
primary and recurrent uveal melanoma and the efficacies of
systemic therapies after recurrence. We also delineated a
prognostic model that could effectively identify different risk
groups based on initial clinical parameters.  
Materials and Methods
1. Patients and data collection
We retrospectively reviewed the medical records of 226
patients who were diagnosed with stage I-III uveal mela-
noma between January 1990 and December 2015 at the 
Department of Ophthalmology, Yonsei University College
of Medicine and the Yonsei Cancer Center. The inclusion cri-
teria were as follows: (1) a diagnosis of uveal melanoma, (2)
treatment with local resection or radiotherapy at the time of
diagnosis, (3) no distant metastases at the time of diagnosis,
and (4) available clinical data at the time of treatment. 
We collected baseline clinical variables, including age, sex,
and co-morbidities, and tumor data, including location, size,
initial stage, and histology. Histologic classification of the
primary uveal melanoma was performed through the enu-
cleation report, local excision or ciliary body excision. The
largest basal diameter (LBD) and depth of each tumor were
measured using B-scan ultrasonography (Ellex, Adelaide,
SA, Australia). Tumor staging was based principally on the
Guideline for Uveal Melanoma from the American Joint
Committee on Cancer (AJCC) Cancer Staging Manual, sev-
enth edition [10].  
2. Treatment 
Local radiotherapy was performed as described in previ-
ous studies [11,12]. Brachytherapy with 106Ru plaques (Eck-
ert & Ziegler BEBIG, Berlin, Germany) was primarily per-
formed as an eye-sparing treatment. The range of target 
radiation doses to the tumor apex was 85-100 Gy. Some 
patients also received adjuvant trans-pupillary thermother-
apy (TTT) using a diode laser with a slit-lamp delivery sys-
tem at 3-month intervals, based on therapeutic responses.
The exposure duration was 1 minute per spot, and the laser
power was adjusted until the tumor surface became gray-
to-white within 1 minute.
Primary enucleation was performed for large tumors. 
Patients who strongly refused enucleation underwent
brachytherapy. A surgical biopsy was performed when his-
tologic confirmation was required. External sclerouvectomy
was generally performed for ciliary body melanoma and 
anterior choroidal melanoma; endoresection via trans pars
plana vitrectomy (TPPV) was performed for posterior
choroidal melanoma [13-15].
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Characteristic Total No recurrence Recurrence p-valuea)(n=226) (n=177) (n=49)
Age, median (range, yr) 53.0 (18-71) 54.0 (18-71) 50.0 (19-61) 0.232
Sex
Male 109 (48.2) 84 (46.2) 28 (53.8) 0.158
Female 117 (51.8) 98 (53.8) 24 (46.2)
Location
Choroid 220 (97.3) 173 (97.7) 47 (95.9) 0.613
Ciliary body 6 (2.7) 4 (2.3) 2 (4.1)
Histology (n=99)
Epithelioid 43 (43.4) 33 (53.2) 10 (27.0) 0.024
Spindle 18 (18.2) 11 (17.7) 7 (18.9)
Mixed 38 (38.4) 18 (29.0) 20 (54.1)
Size, median (range, mm)
Largest basal diameter 10.2 (1.10-30.9) 10.0 (1.1-21.0) 12.0 (4.0-32.0) 0.001
Depth 6.2 (1.10-757.9) 6.0 (1.10-757.0) 7.75 (1.5-18.0) 0.539
Stage (n=104)
I 26 (25.0) 25 (32.5) 1 (3.7) 0.004
II 66 (63.5) 45 (58.4) 21 (77.8)
III 12 (11.5) 7 (9.1) 5 (18.5)
Local treatment
RTxb) 160 (70.8) 136 (76.8) 24 (49.0) < 0.001
Excisionc) 66 (29.2) 41 (23.2) 25 (51.0)
Co-morbidity
None 139 (61.5) 107 (60.5) 32 (65.3) 0.772
Cardiovascular disease 7 (3.1) 6 (3.4) 1 (2.0)
HTN 56 (24.8) 45 (25.4) 11 (22.4)
DM 22 (9.7) 18 (10.2) 4 (8.2)
HBV carrier 7 (3.1) 5 (2.8) 2 (4.1)
Othersd) 17 (7.5) 14 (7.9) 3 (6.1)
BAP1 expression (IHC) > 5%
Primary tumor tissue (n=69)
No 13 (18.8) 10 (22.7) 3 (12.0) 0.349
Yes 56 (81.2) 34 (77.3) 22 (88.0)
Metastasis tumor tissue (n=20)
No - - 7 (35.0) 0.354
Yes - - 13 (65.0)
Recurrence site
Liver - - 43 (87.7) < 0.001
Bone - - 11 (22.4)
Lung - - 3 (6.1)
Otherse) - - 6 (12.2)
First systemic treatment after recurrence
Chemotherapyf) - - 35 (71.4) -
Immunotherapyg) - - 4 (8.2)
Radiotherapyh) - - 3 (6.1)
TACE, RFA on liver metastasis - - 4 (8.2)
Metastatectomyi) - - 7 (14.3)
Observation - - 8 (16.3)
Table 1. Baseline characteristics of primary and metastatic uveal melanoma
(Continued to the next page)
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Forty-nine patients who developed distant recurrences fol-
lowing initial local treatment underwent metastasectomy
and/or palliative first-line systemic treatments comprising
chemotherapies and immunotherapies.
3. Immunohistochemistry
Tumor immunohistochemistry (IHC) was performed
using a Ventana XT automated staining system (Ventana
Medical Systems, Tucson, AZ) according to the manufac-
turer’s protocol in the 69 primary and 20 metastatic uveal
melanoma tissues. Four-micron-thick sections were immu-
nostained with primary antibodies specific for BAP1 (1:50,
C-4, mouse monoclonal, Santa Cruz Biotechnology, Dallas,
TX), which yielded a nuclear staining pattern. BAP1 expres-
sion was determined according to the percentage of BAP1-
positive cells among all melanoma cells. Samples with a
BAP1-positive cell frequency of < 5% were considered to
have lost BAP1 expression.
4. Statistical analysis
For the analysis, datasets were classified as “before” or
“after” distant recurrence. Before recurrence, we reviewed
the primary tumor characteristics and local treatment effica-
cies. Recurrence-free survival (RFS) was defined as the time
from the initial diagnosis of uveal melanoma to the time of
distant recurrence. After recurrence, we reviewed medical
records concerning recurrence patterns and the efficacies of
systemic palliative treatment and surgery. The disease con-
trol rate (DCR) was defined as the proportion of patients who
achieved a complete response, confirmed partial response,
or stable disease per the Response Evaluation Criteria in
Solid Tumors (RECIST) ver. 1.1. PFS was defined as the time
interval from the initiation of first-line systemic therapies to
the date of documented disease progression or death from
any cause. OS1 was measured from the date of initial diag-
nosis with uveal melanoma to the date of death from any
cause, and OS2 was measured from the date of distant recur-
rence to the date of death from any cause.
The primary endpoint of the study, OS2, was calculated
using the Kaplan-Meier product-limit method, and survival
rates were compared statistically using the log-rank test and
generalized Wilcoxon test. All univariate analyses included
the following factors: age, sex, histology, size, tumor stage
and location, distant metastasis pattern, and treatment
modality. The multivariate analysis was performed using
stepwise Cox proportional hazards regression modeling. 
p-values of < 0.05 were considered statistically significant,
and all p-values corresponded to two-sided significance
tests. Data were analyzed using SPSS software ver. 23.0 (IBM
Corp., Armonk, NY). 
5. Ethical statement
This study was reviewed and approved by the Institu-
tional Review Board of Yonsei Cancer Center (IRB 4-2016-
0300). Our institutional review board approved this retro-
spective study and waived the requirement to obtain 
informed consent. 
Characteristic Total No recurrence Recurrence p-valuea)(n=226) (n=177) (n=49)
Largest linear dimension of largest metastatic tumor (n=51), - - 25.0 (4-94) -
median (range, mm)
Table 1. Continued
Values are presented as number (%) unless otherwise indicated. RTx, radiotherapy; HTN, hypertension; DM, diabetes mellitus;
HBV, hepatitis B virus; BAP1, BRCA1-associated protein-1; IHC, immunohistochemistry; TACE, transarterial chemoemboliza-
tion; RFA, radiofrequency ablation. a)Comparison betTeen patients with experience of recurrence or not, b)Includes brachyther-
apy, gamma-knife radiotherapy, and transpupillary thermotherapy, c)Includes enucleation, excision, exentration, and trans
pars plana vitrectomy, d)Includes benign prostate hyperplasia, old TBc, other malignancy, and thyroid disease, e)Includes nasal
cavity, breast, spleen, brain, and adrenal gland metastasis, f)Includes dacarbazine, cisplatin, topotecan, dacarbazine+
cisplatin+vincristine, and 5-fluorouracil+carboplatin, g)includes ipilimumab and interferon, h)Includes radiotherapy to the
nasal cavity, spine, adrenal gland, and brain, i)Includes splenectomy, liver wedge resection, adrenalectomy, lung lobectomy,
skull craniectomy, and maxillectomy.
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Results
1. Baseline characteristics of patients with primary and
metastatic uveal melanoma 
The baseline characteristics of 226 patients are provided in
Table 1. The median age was 53.0 years (range, 18 to 71
years), and 109 patients (48.2%) were male. The most com-
mon primary tumor location was the choroid (n=220, 97.3%),
and the most common histologic types were epithelioid
(n=43, 43.4%) and mixed cell (n=38, 38.4%). The median
tumor thickness was 6.2 mm (range, 1.10 to 757.9), and the
median LBD was 10.2 mm (range, 1.1 to 30.9). According to
the AJCC seventh edition prognostic staging definitions, 26
(25.0%), 66 (63.5%), and 12 (11.5%) patients had stage I, II,
Fig. 1.  Immunohistochemistry (IHC) analysis of primary uveal melanomas without (A) and with BRCA1 associated pro-
tein-1 (BAP1) expression (B) (400). Analysis of recurrence-free survival (RFS, defined as the time from uveal melanoma 
diagnosis to recurrence) according to BAP1 expression (C). Analysis of overall survival from distant recurrence to death
(OS2) according to BAP1 expression in metastatic tissues (D). CI, confidence interval; N/A, not available.
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and III disease, respectively. An IHC analysis identified 56
BAP1-positive samples (81.2%) among 69 available primary
tumor tissues. 
Forty-nine patients (21.6%) with primary uveal melanoma
developed distant recurrences after local treatment. The
baseline characteristics of these patients are also provided in
Table 1. The most common location and histologic type of
these recurrent uveal melanomas were choroid (n=47, 95.9%)
and mixed cell (n=20, 54.1%), respectively. The most com-
mon site of distant recurrence was the liver (n=43, 87.7%),
followed by the bone (n=11, 22.4%) and lung (n=3, 12.2%). 
2. Treatment outcomes for primary and metastatic uveal
melanoma
Following a diagnosis of primary uveal melanoma, 160 
patients (70.8%) were treated with local radiotherapy, includ-
ing 106Ru brachytherapy combined with TTT and gamma-
knife radiotherapy; 66 patients (29.2%) underwent excision,
including primary enucleation, local resection, and TPPV. An
analysis of RFS and OS1 according to treatment modality 
revealed a significantly longer in local radiotherapy than in
excision (not reached vs. 82.0 months: 95% confidence inter-
vals [CI], not available [N/A] vs. 43.8-120.2; p < 0.001; not
reached vs. 79.5 months: 95% CI, N/A vs. 33.0-126.0; 
p < 0.001). 
Forty-nine patients with distant recurrences of uveal
melanoma underwent metastasectomy (n=7, 14.3%), transar-
terial chemoembolization (TACE) or radiofrequency ablation
(RFA) (n=4, 8.2%), local radiotherapy (n=3, 6.1%), or pallia-
tive systemic treatments, including chemotherapy and 
immunotherapy (n=27, 55.1%). Twelve patients who under-
went metastasectomy, TACE/RFA, or radiotherapy subse-
quently received first-line palliative systemic treatment 
(S1 Fig.). The first-line systemic chemotherapy regimens 
included dacarbazine (n=27, 77.1%), platinum-based agents
(n=7, 20.0%), and topotecan (n=1, 2.9%). The first-line 
immunotherapies included interferon (n=1, 2.9%) and ipili-
mumab (n=3, 8.6%). Patients received a mean of 2.94 lines of
palliative systemic treatment.  
Characteristic No. Median RFS p-value
Univariate analysis Multivariate analysis
(95% CI, mo) HR 95% CI p-value HR 95% CI p-value
Age, median (range, yr)
< 30 17 163.0 (N/A) 0.929 1
30-60 141 Not reached 0.83 0.324-2.140 0.703 - - -
> 60 68 Not reached 0.85 0.293-2.467 0.765 - - -
Sex
Male 109 Not reached 0.062 1.71 0.965-3.043 0.066 - - -
Female 117 163.0 (N/A) 1
Location
Choroid 220 163.0 (N/A) 0.452 1
Ciliary body 6 88.0 (N/A) 1.71 0.414-7.048 0.459 - - -
Size
Largest basal diameter (mm) 
(n=223)
< 15 201 163.0 (N/A) < 0.001 1 1
 15 22 25.0 (0.00-61.18) 4.73 2.326-9.598 < 0.001 2.75 1.092-6.904 0.032
Depth (mm) (n=224)
< 10 193 163.0 (N/A) < 0.001 1 1
 10 31 54.0 (N/A) 3.37 1.804-6.308 < 0.001 3.07 1.266-7.468 0.013
Stage (n=104)
I 26 Not reached 0.012 1
II 66 82.0 (48.40-115.60) 8.44 1.134-62.787 0.037 - - -
III 12 25.0 (N/A) 15.04 1.752-129.043 0.013 - - -
Total 226 163.0 (N/A)
Table 2. Univariate and multivariate analyses of risk factors affecting the recurrence of primary uveal melanoma
RFS, recurrence-free survival (time from the initial diagnosis of uveal melanoma to distant recurrence); CI, confidence inter-
val; HR, hazard ratio; N/A, not available.
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Among patients with distant recurrences of uveal mela-
noma, the DCR was analyzed according to treatment modal-
ity. Here, 71.4% (5/7) of patients with in metastasectomy
followed by first-line systemic therapy, 33.3% (9/29) of those
receiving only first-line systemic therapy, and 0% of those
receiving TACE or RFA or palliative radiotherapy followed
by first-line systemic therapy achieved disease control 
(S2 Table). An analysis of median OS2 duration yielded val-
ues of 134.7 (95% CI, 0.0 to 307.6), 8.0 (95% CI, 6.8 to 9.2), 9.2
(95% CI, N/A), 15.7 (95% CI, 13.2 to 18.1), and 7.6 months
(95% CI, 0.0 to 25.2) for patients who underwent metastasec-
tomy, TACE or RFA, palliative radiotherapy, only systemic
treatments, and observation alone, respectively. 
The median OS1 of overall 226 primary uveal melanoma
patients was 151.6 months (95% CI, 91.0 to 212.2) and the 
median OS2 of distant recurrent patients was 15.7 months
(95% CI, 13.1 to 18.2).
3. Analysis of prognostic factors 
1) BAP1 expression in primary and metastatic uveal mela-
nomas
In accordance with a previous study [8], we subjected 69
primary and 20 metastatic uveal melanoma tissues to BAP1
IHC (Fig. 1A and B). The loss of BAP1 expression was more
frequent among metastatic tumor tissues than among pri-
mary tissues (13/69 [18.8%] vs. 7/20 [35.0%]) (Table 1). 
Patients with BAP1-negative primary tumor tissues had a
longer median RFS when compared with their BAP1-positive
counterparts, although this difference was not statistically
significant (not reached vs. 82.0 months, p=0.268) (Fig. 1C).
However, patients with BAP1-negative metastatic tumor tis-
sues had a shorter OS2 when compared to those with BAP1-
positive tissues; again, this difference was not statistically
significant (15.7 months vs. 24.4 months, p=0.216) (Fig. 1D).
Fig. 2.  Analysis of recurrence-free survival (RFS, defined as the time from choroidal melanoma diagnosis to recurrence) 
according to risk factors for recurrence of primary uveal melanoma (A). (B) Subgroup analysis according to local treatment
with  1 risk factor. CI, confidence interval; N/A, not available. a)Includes tumor basal diameter  15 mm, depth  10 mm,
b)Includes brachytherapy, gamma-knife radiotherapy, transpupillary thermotherapy, c)Includes trans pars plana vitrectomy,
enucleation, excision, exentration.
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Fig. 3.  Analysis of overall survival from distant recurrence to death (OS2) according to survival-related risk factors in patients
with metastatic uveal melanoma (A). (B) Subgroup analysis of high-risk patients ( 2 risk factors) according to systemic ther-
apy or supportive care. (C) Subgroup analysis of low-risk patients ( 1 risk factor) according to the type of systemic treatment.
CI, confidence interval. a)Includes male sex, largest linear dimension of largest metastatic tumor  45 mm, recurrence-free
survival < 50 months.
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2) Prognostic recurrent risk factors analysis of primary
uveal melanoma
We next analyzed prognostic factors for the recurrence of
primary uveal melanomas following local treatments, as pre-
viously mentioned, to enhance risk-based patient stratifica-
tion. In a univariate analysis, LBD  15 mm (p < 0.001), depth
 10 mm (p < 0.001), and stage II or III disease (p=0.037 and
p=0.013, respectively) were found to have significant adverse
effects on relapse (Table 2). A subsequent multivariate analy-
sis included the clinical parameters of age, sex, location,
tumor stage and size, and local treatment administration. A
forward Cox regression model analysis identified the follow-
ing significantly poor prognostic factors for relapse (Table 2):
tumor basal diameter  15 mm (hazard ratio [HR], 2.75; 95%
CI, 1.09 to 6.90; p=0.032), and depth  10 mm (HR, 3.07; 95%
CI, 1.27 to 7.47; p=0.013). 
Next, 226 patients were divided into three subgroups
based on multivariate results to identify those who would
potentially benefit from primary local treatments: patients
without any risk factors and those with 1-2 risk factors 
(Fig. 2A). Among the 41 patients with one or more risk fac-
tors, those who underwent local radiotherapy had a longer
median RFS, compared to those who underwent local exci-
sion (not reached vs. 19.0 months; 95% CI, N/A vs. 8.40-
29.60; p=0.004) (Fig. 2B).
3) Analysis of prognostic and survival risk factors for 
recurrent uveal melanoma
The univariate analysis identified the recurrence site (liver
only, p=0.013), a largest linear metastatic tumor dimension
 45 mm (p=0.025), and RFS < 50 months (p=0.011) as signif-
icantly poor prognostic factors for progression despite first-
line systemic treatment (Table 3). In a multivariate analysis,
the recurrence site (liver only; HR, 6.98; 95% CI, 1.20 to 40.42;
p=0.030) and RFS < 50 months (HR, 8.08; 95% CI, 1.82 to
35.84; p=0.006) remained significantly poor prognostic fac-
tors for PFS after first-line systemic therapy. 
Regarding survival after recurrence, another univariate
analysis identified male sex (p=0.004), a largest linear
metastatic tumor dimension  45 mm (p=0.005), and RFS 
< 50 months (p=0.019) as factors with significant negative 
adverse effects on OS2 (Table 3). A forward Cox regression
model analysis subsequently identified male sex (HR, 3.79;
95% CI, 1.34 to 10.72; p=0.012), a largest linear metastatic
tumor dimension  45 mm (HR, 5.48; 95% CI, 1.36 to 22.18;
p=0.017), and short RFS (HR, 4.89; 95% CI, 1.38 to 17.29;
p=0.014) as significantly poor prognostic factors for survival
after recurrence. Based on the multivariate analysis findings,
49 patients with distant recurrences of uveal melanoma were
divided into four subgroups, and OS2 was found to decrease
significantly as the number of risk factors increased (Fig. 3A).
Among the 25 patients with two or more risk factors (high-
risk group), 19 who received palliative first-line systemic
treatment had a significantly longer OS2, compared to those
who received supportive care only (13.7 months vs. 4.3
months, p=0.042) (Fig. 3B). Seventeen of 20 patients with one
or no risk factors (low-risk group) received first-line systemic
therapy and in this group, first-line chemotherapy yielded a
longer OS2 relative to immunotherapy (25.3 months vs. 8.0
months, p=0.004) (Fig. 3C). 
Discussion
Up to 50% of patients with uveal melanoma will develop
metastatic disease after primary local treatment [16]. Such
cases are faced with a very poor prognosis and limited ther-
apeutic options with low response rates. Several previous
studies have reported the risk factors and characteristics of
recurrent uveal melanoma [2-4,10,14,17-19]. 
In Korean patients, uveal melanomas tend to exhibit ver-
tical growth, with relatively large apical heights and small
LBDs [11]. In such cases, the initial radiation doses provided
via brachytherapy at the time of diagnosis are insufficient to
reach the basal level of the tumor, leading to frequent local
and/or distant recurrences and an increased need for enu-
cleation or systemic therapy. Regarding local treatment, our
study found that 136 patients (76.8%) in the non-recurrent
group received local radiotherapy, while 25 (51.0%) in the 
recurrent group underwent primary enucleation. Moreover,
when compared with non-recurrent tumors, recurrent 
tumors had a significantly larger primary tumor basal size
and significantly more advanced stage. The AJCC Oph-
thalmic Oncology Group reported that an increasing tumor
size was consistent with an increased risk of metastasis [10],
and a Taiwanese trial found associations of a larger tumor
size and epithelioid or mixed cell type with distant metasta-
sis [17]. Our findings were also supported by prior studies
in which patients who underwent with primary enucleation
had a higher recurrence rate than did those treated with 
irradiation [4].
As noted previously, Harbour et al. [7] reported an inacti-
vating somatic mutation in BAP1, located on chromosome
3p21.1, in 47% of all uveal melanomas; 96% of tumors har-
boring this mutation later metastasized. Koopmans et al. [8]
confirmed that this somatic BAP1 mutation correlated
strongly with BAP1 expression, and reported an eight-fold
increase in the risk of metastasis among patients with BAP1-
negative or mutated BAP1-expressing uveal melanoma. In
our study, however, we found that BAP1 expression in the
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primary tumor was associated with a shorter RFS, compared
to a loss of BAP1 expression. Our multivariate analysis fur-
ther identified two risk factors associated with distant recur-
rence: tumor basal diameter  15 mm and vertical depth  10
mm. We further found that in patients with at least one risk
factor, local radiotherapy was more effective than local exci-
sion or enucleation in terms of RFS prolongation. Accord-
ingly, we recommend that treatment strategies for primary
uveal melanoma should be based on these risk factors.
Other investigators have described the patterns of metasta-
tic spread in patients with uveal melanoma [20-23]. Although
the liver and lung are the most frequent sites of metastasis,
the sites and extent of dissemination vary among studies and
reflect differences in study populations, designs, diagnostic
tools, and data collection over time. Therefore, the Collabo-
rative Ocular Melanoma Study (COMS) protocol specifies an
annual follow-up of patients, including a routine medical 
examination, liver function studies, and chest X-ray exami-
nation [24]. In addition, Hicks et al. [25] recommended rou-
tine liver ultrasonography follow-ups after determining the
poor sensitivity of a single liver function test for metastatic
disease. In our study, the first distant metastatic site in 38 
patients (77.6%) was a single organ. Although the liver was
the first metastatic site in 81.6% of patients with single-organ
involvement and 63.3% of all patients, nearly 40% of all 
patients presented with non-liver sites of first metastasis
(mainly bone). This finding suggests that liver-only screening
procedures would miss a substantial proportion of patients.
Therefore, guidelines for periodic systemic surveillance
should be established for patients in Asia, and particularly
those in Korea who have undergone definitive local treat-
ment for primary uveal melanoma. 
Although metastatic uveal melanoma is considered a sub-
stantial problem, relatively few studies have addressed fac-
tors associated with survival. The median survival times of
the two largest unselected groups of patients with metastatic
uveal melanoma in the COMS and Harvard study were 3.6
and 3.7 months [26,27]. The COMS study reported 1-year and
2-year survival rates of only 19% and 8%, respectively [27].
In our study, we observed a median OS2 of 15.7 months, in
contrast to previous studies. We might attribute this discrep-
ancy to the fact that all patients in our study population 
received local ocular treatment at the time of primary uveal
melanoma diagnosis and remained disease-free for a median
of 38.1 months. In contrast to previous studies that included
only patients initially diagnosed with stage IV disease, we
might have observed a lower level of aggressiveness because
the recurrences occurred substantially later after local treat-
ment. Additionally, our study included patients who 
received palliative treatments after metastasectomy from the
liver, adrenal gland, or breast mass or after radiotherapy. In
a more accurate comparison of patients who underwent
metastasectomy with those who received only systemic first-
line treatment, the former had a significantly longer survival
duration. In addition, patients who received only supportive
care had a significantly longer median OS2 duration, com-
pared to those than those who received TACE, RFA, or 
radiotherapy. Therefore, we would expect the surgical resec-
tion of metastatic lesions to yield survival benefits. 
In various studies of different groups of patients with
metastatic uveal melanoma, the investigators identified mul-
tiple predictors of survival duration after the diagnosis of
metastasis. The identified poor prognostic factors included
patient age, male sex, symptomatic tumor, poor performance
status, short metastasis-free interval, anatomic site with
metastatic involvement (i.e., hepatic involvement), large
number of metastatic sites, and metastatic lesion size [4,28].
In our study, a multivariate analysis identified male sex, a
largest linear metastatic tumor diameter  45 mm, and a short
RFS as prognostic factors associated with OS2. As previously
observed, high-risk patients ( 2 risk factors) who received
systemic first-line therapy after distant recurrence had a
longer survival duration, compared to those treated with
only supportive care. Therefore, high-risk patients should be
identified and treated with systemic therapies, as this would
be expected to improve survival rates. 
Medical oncologists are required to select from among
chemotherapy, immunotherapy, or targeted agents when 
determining the systemic treatment most likely to improve
the survival of a patient with metastatic uveal melanoma.
However, no effective systemic treatment method has yet
been identified, and no reports of non-randomized phase III
clinical trials of any alternative or other specific treatments
have been published. We note that in our study, the first-line
treatments provided for metastatic uveal melanoma varied
considerably by subgroup and included surgery, TACE,
and/or radiotherapy. The retrospective design of our study
limited our analysis of the effect of systemic treatment after
relapse. However, given the heterogeneous nature of treat-
ments received by patients in this study, we should be care-
ful when interpreting the efficacies of these first-line systemic
treatments. We further note that we have not identified an
ideal first-line systemic therapeutic strategy that significantly
improved survival, although among patients who received
only palliative systemic treatment without surgery, TACE,
or radiation for metastatic lesions, those treated with chemo-
therapy had a significantly longer median OS2, compared to
those receiving mmunotherapy (S3 Table). A similar OS2
outcome was also observed among low-risk patients. Among
patients receiving only first-line chemotherapy (n=26), a plat-
inum-based regimen was associated with a longer PFS rela-
tive to dacarbazine or topotecan. However, dacarbazine
seemed to elicit a more durable response and longer OS2
when compared with platinum-based and topotecan, 
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although these differences were not statistically significant
(S4 Fig.).
Our study had the following strengths. In our cohort, 
approximately 40% of patients presented with a non-hepatic
first metastasis, which suggests that liver-only screening
strategies are likely to fail. Accordingly, bone and chest 
examinations should also be included in screening protocols,
as the early detection of recurrent metastatic lesions will 
increase the likelihood of surgical resection. Notably, metas-
tasectomy correlated with improved survival in our dataset.
Furthermore, relevant studies specific to Asian populations
are limited. Our study, which assessed real efficacy in a pop-
ulation of Korean patients, therefore provides important 
information. Moreover, clinical data were used to score the
factors related to overall survival after recurrence and to sug-
gest treatment strategies. 
However, this study also had two main limitations. First,
we did not conduct gene expression profiling or a full analy-
sis of mutations in genes such as GNAQ, GNA11, or BAP1,
which are known poor prognosticators in uveal melanoma.
Instead, we confirmed BAP1 expression in primary and
metastatic tissues using IHC. Our finding of a high risk of 
recurrence among patients with BAP1-positive primary
tumor tissues contrasted with a previous report [8]. On the
other hand, van Essen et al. [29] reported that low RNA lev-
els of BAP1 and negative IHC for BAP1 were predictive of
death due to metastasis of uveal melanoma. We also obser-
ved an association of the loss of BAP1 expression in metasta-
tic tumors with poor survival in patients with recurrent uveal
melanoma patients. These inter-study discrepancies suggest
that we should validate our findings using a BAP1 mutation
analysis. Second, this study was performed at a single center
and featured a retrospective design, and we were unable to
compare the effects associated with immunotherapy, chemo-
therapy, and targeted agent therapy because of the small
number of patients with distant recurrences. Therefore, mul-
ticenter prospective studies are needed to further estimate
the effects of treatment on survival in patients with recurrent
uveal melanoma.
In conclusion, the present study conducted a multivariate
analysis of clinical and histologic data to identify risk factors
related to recurrence in patients with primary uveal mela-
noma and survival in those with distant recurrent uveal
melanoma. Our findings suggest that patients with primary
uveal melanoma and one or more risk factors would more
strongly benefit from local radiotherapy (vs. local excision or
primary enucleation) for recurrence prevention. We also
found that for “high risk” patients with recurrent uveal
melanoma, more aggressive systemic first-line chemothera-
peutic regimens and surgical treatment would likely 
improve survival. Finally, a multidisciplinary approach com-
bining ophthalmology, radiation oncology, general surgery,
and medical oncology should help to improve overall sur-
vival in patients with primary and recurrent uveal mela-
noma.
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